Literature DB >> 17478088

Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.

Angélique Gougelet1, Stefan O Mueller, Ken S Korach, Jack-Michel Renoir.   

Abstract

Oestrogen receptors (ER)alpha and beta modify the expression of genes involved in cell growth, proliferation and differentiation through binding to oestrogen response elements (EREs) located in a number of gene promoters. Transient transfection of different luciferase reporter vectors 3xEREs-Vit, 2xEREs-tk and ERE-C3 showed that the transactivation capacity of both ER subtypes was influenced by 1) the nature of the inducer (oestradiol (E2), phyto- and anti-oestrogen (AE)), 2) the structure of the promoter (nucleotidic sequence, number of ERE, length of the promoter sequence) and 3) the cell line (containing endogenous ER (MCF-7) or in which ER was stably expressed (MDA-MB-231-HE-5 (ERalpha+) or MDA-MB-231-HERB (ERbeta+)). ER subtype did not display the same efficacy on the different constructions in the presence of E2 and of AE according to the cell (e.g. in MCF-7 cells: tk>>Vit>>C3 approximately 0 while in MDA-MB-231 cells: Vit>>tk approximately C3). E2 response was higher in MCF-7 cells, probably due to higher ER expression level (maximal at 10(-10)M instead of 10(-8)M for E2 in HE-5 cells). Finally, the same ligand could exert opposite activities on the same promoter according to the ER isoform expressed: in the MDA-MB-231 cells, AE acted as inducers of the C3 promoter via ERbeta whereas ERalpha/AE complexes down-regulated this promoter. Approximately 70% of breast tumours express ER and most tumour cells coexpress both ER isotypes. Thus, different types of ER dimers can be formed in such tumours (ERbeta or ERalpha homodimers or ERalpha/ERbeta heterodimers). We therefore studied the influence of the coexistence of the two ERs on the ligand-induced transcriptional process following transient transfection of ERalpha in ERbeta+ cells, and inversely ERbeta in ERalpha+ cells. ERbeta-transfection inhibited the E2- and genistein-induced ERalpha-dependent transcription on all promoters in all cell lines except C3 in MCF-7; this inhibitory effect was lost following transfection of ERbeta deleted of its AF-1 (ERbeta-AF-2). These results suggest that the dominant negative properties of ERbeta are mainly due to its AF-1 function. Interestingly, transfection of an ERbeta-AF-2 construct into MCF-7 cells potentiated the transcription inhibitory capacity of 4-OH-tamoxifen (OHT) on the Vit and tk promoters. Thus, (1) OHT exerts an agonistic activity through the AF-1 function of ER and (2) expression of ERbeta in breast cancer cells seems to favour the AE treatment. Contrary to ERbeta, ERalpha-transfection had little effect on ERbeta transactivation capacity in HERB cells. Finally, the ratio ERalpha/ERbeta constitutes one decisive parameters to orientate the transcriptional mechanism of a target gene in the presence of agonist as well as of antagonist ligands.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478088     DOI: 10.1016/j.jsbmb.2007.03.002

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  13 in total

Review 1.  The role of estrogens and estrogen receptors in normal prostate growth and disease.

Authors:  Gail S Prins; Kenneth S Korach
Journal:  Steroids       Date:  2007-11-12       Impact factor: 2.668

2.  Developmental programming: impact of fetal exposure to endocrine-disrupting chemicals on gonadotropin-releasing hormone and estrogen receptor mRNA in sheep hypothalamus.

Authors:  Megan M Mahoney; Vasantha Padmanabhan
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-04       Impact factor: 4.219

Review 3.  Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Authors:  Stéphanie Légaré; Mark Basik
Journal:  Mol Endocrinol       Date:  2016-07-20

Review 4.  Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease.

Authors:  Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-01

Review 5.  Vascular effects of estrogenic menopausal hormone therapy.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Rev Recent Clin Trials       Date:  2012-02

6.  Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease.

Authors:  Graciliano R A do Nascimento; Yaskara V R Barros; Amanda K Wells; Raouf A Khalil
Journal:  Curr Hypertens Rev       Date:  2009-11

Review 7.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

8.  Developmental programming: prenatal androgen excess disrupts ovarian steroid receptor balance.

Authors:  Hugo H Ortega; Natalia R Salvetti; Vasantha Padmanabhan
Journal:  Reproduction       Date:  2009-03-04       Impact factor: 3.906

9.  Identification of estrogen receptor β as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3β.

Authors:  Nathalie Picard; Véronique Caron; Stéphanie Bilodeau; Mélanie Sanchez; Xavier Mascle; Muriel Aubry; André Tremblay
Journal:  Mol Cell Biol       Date:  2012-05-14       Impact factor: 4.272

10.  Comparative effects of R- and S-equol and implication of transactivation functions (AF-1 and AF-2) in estrogen receptor-induced transcriptional activity.

Authors:  Svitlana Shinkaruk; Charlotte Carreau; Gilles Flouriot; Catherine Bennetau-Pelissero; Mylène Potier
Journal:  Nutrients       Date:  2010-03-15       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.